Perform initial in vitro screening of drug candidates for SARS-CoV-2
Determine EC50 and CC50 for the most promising candidates screened in Aim 1 against SARS-CoV-2 and other priority BSL3 pathogens
Perform in vivo testing of select antivirals to identify new therapeutic candidates
Define drug efficacy, toxicity, and mechanism of action in Air- Liquid-Interface(ALI) model and human adult lung organoids (ALOs)
The National Institute for Allergy and Infectious Diseases has awarded Jeffrey Glenn, MD, PhD, professor of hepatology and gastroenterology and of microbiology and immunology, $69 million...
Read More
A single dose of lambda-interferon reduced hospitalization among COVID-19 outpatients in a late-stage study spearheaded by a Stanford Medicine virologist.
Read More 
The Antiviral Program for Pandemics (APP) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential.
Read More 
